aminophenazone cyclamate Report issue

Small molecule Experimental
ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Aminophenazone is a phenyl-pyrazolone derivative with potent analgesic and antipyretic properties. Aminophenazone has been used as salt or complexes, including topically as the salicylate. It was recommended for the treatment of a fever, neuralgia, myositis, acute rheumatism, arthritis, chorea. In 1999 the FDA suspended aminophenazone. The drug caused agranulocytosis. Some of the cases of agranulocytosis were fatal. Another reason for suspending this drug from the market was its ability to react with nitrite-containing food, thus forming carcinogenic nitrosamines. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of cytochrome P-450 metabolic activity in liver function tests.   NCATS

Chemistry

  • SMILES: CN(C)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2
  • InChIKey: RMMXTBMQSGEXHJ-UHFFFAOYSA-N
  • Mol. Mass: 231.2936
  • ALogP: 1.55
  • ChEMBL Molecule:
    aminopyrine  
More Chemistry

Pharmacology

Alternative names

1,5-dimethyl-4-dimethylamino-2-phenyl-3-pyrazolone | 1-phenyl-2,3-dimethyl-4-(dimethylamino)-5-pyrazolone | 1-phenyl-2,3-dimethyl-4-dimethylaminopyrazol-5-one | 2,3-dimethyl-4-dimethylamino-1-phenyl-5-pyrazolone | 3-keto-1,5-dimethyl-4-dimethylamino-2-phenyl-2,3-dihydropyrazole | 4-(dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl-3h-pyrazol-3-one | 4-(dimethylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3h-pyrazol-3-one | 4-dimethylamino-1-phenyl-2,3-dimethylpyrazolone | 4-dimethylamino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one | 4-dimethylamino-2,3-dimethyl-1-phenyl-5-pyrazolone | 4-dimethylaminoantipyrine | 4-(dimethylamino)antipyrine | 4-dimethylaminophenazone | amidazophen | amidazophene | amidofebrin | amidofen | amidophen | amidophenazone | amidopyrazoline | amidopyrin | amidopyrine | aminofenazona | aminofenazone | aminophenazon | aminophenazone | aminophenazone cyclamate | aminophenazonum | aminopyrin | aminopyrine | anafebrina | dimethylaminoantipyrine | dimethylaminoazophene | dimethylaminophenazon | dimethylaminophenazone | (dimethylamino)phenazone | dimethylaminophenyldimethylpyrazolone | dimethylaminophenyldimethylpyrazone | dipyrine | pyramidon | pyramidone

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Migraine Disorders

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Arthritis ()

Bronchiectasis (Phase 3)

Migraine Disorders (Phase 2)

Myositis ()

Nerve Fibers (Phase 4)

Neuralgia ()

Prostatic Neoplasms (Phase 4)

Rheumatic Fever ()

Spinal Cord Injuries (Phase 3)

Vestibular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue